Lipoprotein-associated phospholipase A2: A potential new risk factor for coronary artery disease and a therapeutic target

83Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

The recognition that atherosclerosis represents an inflammatory disease has begun to shift interest towards novel therapies that could specifically target the underlying inflammatory component of atherogenesis. Like low-density lipoprotein, an ideal new drug target would be a modifiable plasma risk factor that not only reflects the ongoing inflammatory process but also actively promotes it. Lipoprotein-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new risk factor that may have the potential to fulfil these requirements. © 2001 Elsevier Science Ltd.

Cite

CITATION STYLE

APA

Macphee, C. H. (2001, April 1). Lipoprotein-associated phospholipase A2: A potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology. Elsevier BV. https://doi.org/10.1016/S1471-4892(01)00024-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free